Researchers at Stichting AMC Foundation and Vrije Universiteit van Amsterdam have identified [18F]-labeled pyrazolidine-3,5-dione compounds targeting P2Y purinoceptor 12 (P2RY12; P2Y12) acting as PET and SPECT imaging agents. They are reported to be useful for the diagnosis of multiple sclerosis, Alzheimer’s disease and Parkinson’s disease.

Scientists at Daegu-Gyeongbuk Medical Innovation Foundation and Korea Research Institute of Chemical Technology have synthesized phenaleno-isoquinolinium-based compounds reported to be useful for the treatment of cancer.

Haihe Biopharma Co. Ltd. has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

At the recently concluded American Society of Hematology meeting, F Hoffmann-La Roche Ltd. presented promising results for their next-generation coagulation factor VIIIa (FVIIIa) mimetic bispecific antibody, NXT-007 (RO-7589655), supporting the ongoing phase I/II studies.

Pilatus Biosciences Inc.’s PLT-012 has been awarded orphan drug designation by the FDA for treating liver and intrahepatic bile duct cancer.

Work at the Institute of Materia Medica of Beijing has led to the discovery and preclinical characterization of novel fructose-1,6-bisphosphatase (FBPase) inhibitors as potential therapeutic candidates for the treatment of type 2 diabetes.